Full Text View
Tabular View
No Study Results Posted
Related Studies
Re-expression of ER in Triple Negative Breast Cancers
This study is currently recruiting participants.
Verified June 2013 by Emory University
Study NCT01194908   Information provided by Emory University

First Received on September 1, 2010.   Last Updated on June 6, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Breast Tumors
Breast Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Decitabine, LHB589, Tamoxifen
Additional drug interventions recognized in this trial
Decitabine
Tamoxifen
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Enzyme Inhibitors
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses
Sponsors listed in this trial
Emory University
Novartis
Eisai Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services